NSC 14613

CAS No. 91396-88-2

NSC 14613( NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid )

Catalog No. M16567 CAS No. 91396-88-2

PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 28 In Stock
10MG 47 In Stock
25MG 76 In Stock
50MG 110 In Stock
100MG 160 In Stock
200MG 228 In Stock
500MG 383 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NSC 14613
  • Note
    Research use only, not for human use.
  • Brief Description
    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
  • Description
    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
  • In Vitro
    PluriSIn 1, a small-molecule inhibitor of stearoyl-coA desaturase (SCD), on induced pluripotent stem cells (iPS)-derived cardiomyocytes (CM). PluriSIn 1 treatment significantly decreases the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSIn 1 treatment at 20 μM for 1 day significantly induces the apoptosis of Nanog-positive iPS derivates (iPSD). In addition, PluriSIn 1 treatment at 20 μM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSIn 1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSIn 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which is prevented by treatment with PluriSIn 1. Moreover, treatment with PluriSIn 1 does not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n=4). Importantly, PluriSIn 1-treated iPS-derived CM exhibits the ability to engraft and survive in the infarcted myocardium.
  • In Vivo
    ——
  • Synonyms
    NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    SCD
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    91396-88-2
  • Formula Weight
    213.24
  • Molecular Formula
    C12H11N3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 43 mg/mL (201.65 mM)
  • SMILES
    O=C(NNC1=CC=CC=C1)C2=CC=NC=C2
  • Chemical Name
    N'-phenylisonicotinohydrazide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ben-David U, et al. Cell Stem Cell, 2013, 12(2), 167-179.
molnova catalog
related products
  • Lithium citrate trib...

    Lithium Citrate is the active component of Lithium which is a drug used in treatment of psychiatric disease.

  • AZD1981

    AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors.

  • 11β-HSD1-IN-11

    11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively.